Evidence map›Paper›PMID 39212691›Full record

ArticleRheumatology international2024

Heterogeneity in nomenclature and abbreviation usage for anti-synthetase syndrome: a scoping review.

Anushka Aggarwal, Tanya Chandra, Parth Ladha, Srijan Mittal, Saloni Haldule, Simran Nirmal, Namratha Edpuganti, Nakul Jain, Lorenzo Cavagna, Giovanni Zanframundo and 2 more

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anushka AggarwalDepartment of Rheumatology, Indraprastha Apollo Hospital, New Delhi, India.
Tanya ChandraDepartment of Medicine, Arthritis and Autoimmunity Center and UPMC Myositis Center, Division of Rheumatology and Clinical Immunology, School of Medicine, University of Pittsburgh, BST S 727, 3500 Terrace Street, Pittsburgh, PA, 15261, USA.
Parth LadhaByramjee Jeejeebhoy Medical College, Pune, India.
Srijan MittalMaulana Azad Medical College, New Delhi, India.
Saloni HalduleByramjee Jeejeebhoy Medical College, Pune, India.
Simran NirmalByramjee Jeejeebhoy Medical College, Pune, India.
Namratha EdpugantiMamata Medical College, Telangana, India.
Nakul JainNetaji Subhash Institute of Technology, New Delhi, India.
Lorenzo CavagnaRheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Giovanni ZanframundoRheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Sara Faghihi-KashaniDepartment of Medicine, Arthritis and Autoimmunity Center and UPMC Myositis Center, Division of Rheumatology and Clinical Immunology, School of Medicine, University of Pittsburgh, BST S 727, 3500 Terrace Street, Pittsburgh, PA, 15261, USA.
Rohit AggarwalDepartment of Medicine, Arthritis and Autoimmunity Center and UPMC Myositis Center, Division of Rheumatology and Clinical Immunology, School of Medicine, University of Pittsburgh, BST S 727, 3500 Terrace Street, Pittsburgh, PA, 15261, USA. aggarwalr@upmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-synthetase syndrome constitutes a dynamically evolving subset of Idiopathic Inflammatory Myopathy, however, the nomenclature and abbreviations for this syndrome are plagued by heterogeneity, leading to lack of consistency in literature. The objective of this study is to evaluate existing diversity in disease names and abbreviations, with a future goal to develop consensus on the nomenclature. A scoping review format was used for analysis. A comprehensive PUBMED search was conducted from January 1, 1984 (the initial description of anti-synthetase autoantibodies) to November 30, 2023, encompassing all pertinent articles published within this timeframe. Search terms included, ((antisynthetase syndrome) OR (anti synthetase syndrome)) OR (anti-synthetase syndrome)). The articles were screened for presence of terminology and abbreviations used. The search yielded 936 items with the specified terms. After excluding 303 irrelevant articles and 58 non-English publications, the remaining n = 575 articles underwent detailed review of the abstract and full article. Out of n = 575, 54.7% (n = 314) used 'antisynthetase syndrome' and 43.4% (n = 249) preferred 'anti-synthetase syndrome' with few novel names also. Among these, 394 articles used abbreviations while 181 did not. Most utilized term was ASS; in 64.7% (n = 255), followed AS in 11.9% (n = 47), ASSD in 9.9% (n = 39) and ASyS in 7.6% (n = 30). A discordance in nomenclature is evident, with about half using antisynthetase syndrome and other half using anti-synthetase syndrome. Moreover, significant heterogeneity exists in abbreviation use aswell. There is a pressing need to bridge this disparity and establish a uniform identifier for the disease with an objective to develop greater coherence in future research, educational initiatives, and interdisciplinary collaboration.

Indexed as

MyositisTerminology as TopicAbbreviations as TopicAutoantibodiesHumansAutoantibodiesAnti-synthetase syndromeAntisynthetase syndromeAnti-tRNA-synthetase syndromeASSASSDNomenclature

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.